Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
0–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female children, \<13 years of age
Rapid influenza diagnostic test (RIDT), polymerase chain reaction (PCR), or viral culture positive for influenza
Immunocompromised
Symptoms/signs suggestive of influenza like illness (ILI)
Less than or equal to (\</=) 96 hours between onset of ILI and first dose of study drug
You may not be if
Clinical evidence of severe hepatic impairment
Infants with post-menstrual age (PMA) \<36 weeks
Clinical evidence of significant renal impairment
Allergy to oseltamivir or excipients
Hereditary fructose intolerance
Received anti-viral treatment with activity against influenza (for example amantadine, rimantadine, oseltamivir, laninamivir, peramivir, zanamivir, and ribavirin) or probenecid medication within 2 weeks prior to randomization
Clareo Health | A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
